The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Emerging Mechanisms of Fluoroquinolone Resistance
Open accessAbstract
Broad use of fluoroquinolones has been followed by emergence of resistance, which has been due mainly to chromosomal mutations in genes encoding the subunits of the drugs' target enzymes, DNA gyrase and topoisomerase IV, and in genes that affect the expression of diffusion channels in the outer membrane and multidrug-resistance efflux systems. Resistance emerged first in species in which single mutations were sufficient to cause clinically important levels of resistance (e.g., Staphylococcus aureus and Pseudomonas aeruginosa). Subsequently, however, resistance has emerged in bacteria such as Campylobacter jejuni, Escherichia coli, and Neisseria gonorrhoeae, in which multiple mutations are required to generate clinically important resistance. In these circumstances, the additional epidemiologic factors of drug use in animals and human-to-human spread appear to have contributed. Resistance in Streptococcus pneumoniae, which is currently low, will require close monitoring as fluoroquinolones are used more extensively for treating respiratory tract infections.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Quinolone resistance from a transferable plasmid
Martínez-Martínez, L., Pascual, A., & Jacoby, G. A. (1998) · The Lancet · doi:10.1016/s0140-6736(97)07322-4 · Cited by 1,100
Decreased Susceptibility of Streptococcus pneumoniae to Fluoroquinolones in Canada
Chen, D. K., McGeer, A., de Azavedo, J. C., & Low, D. E. (1999) · New England Journal of Medicine · doi:10.1056/nejm199907223410403 · Cited by 987
Community‐Acquired Pneumonia in Adults: Guidelines for Management
Bartlett, J. G., Breiman, R. F., Mandell, L. A., & File, Jr. (1998) · Clinical Infectious Diseases · doi:10.1086/513953 · Cited by 865
Structure and mechanism of DNA topoisomerase II
Berger, J. M., Gamblin, S. J., Harrison, S. C., & Wang, J. C. (1996) · Nature · doi:10.1038/379225a0 · Cited by 859
Quinolone-Resistant Campylobacter jejuni Infections in Minnesota, 1992–1998
Smith, K. E., Besser, J. M., Hedberg, C. W., Leano, F. T., Bender, J. B., Wicklund, J. H., Johnson, B. P., Moore, K. A., & Osterholm, M. T. (1999) · New England Journal of Medicine · doi:10.1056/nejm199905203402001 · Cited by 666
Endtz, H. P., Ruijs, G. J., van Klingeren, B., Jansen, W. H., van der Reyden, T., & Mouton, R. P. (1991) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/27.2.199 · Cited by 590
Mechanisms of fluoroquinolone resistance
Hooper, D. C. (1999) · Drug Resistance Updates · doi:10.1054/drup.1998.0068 · Cited by 488
Self-citationYoshida, H., Bogaki, M., Nakamura, S., Ubukata, K., & Konno, M. (1990) · Journal of Bacteriology · doi:10.1128/jb.172.12.6942-6949.1990 · Cited by 479
Crystal structure of the breakage–reunion domain of DNA gyrase
Cabral, J. H. M., Jackson, A. P., Smith, C. V., Shikotra, N., Maxwell, A., & Liddington, R. C. (1997) · Nature · doi:10.1038/42294 · Cited by 456
Emergence and Dissemination of Quinolone-Resistant Escherichia coli in the Community
Garau, J., Xercavins, M., Rodríguez-Carballeira, M., Gómez-Vera, J. R., Coll, I., Vidal, D., Llovet, T., & Ruíz-Bremón, A. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.11.2736 · Cited by 337
Cited by
Antimicrobial Resistance in ESKAPE Pathogens
De Oliveira, D. M. P., Forde, B. M., Kidd, T. J., Harris, P. N. A., Schembri, M. A., Beatson, S. A., Paterson, D. L., & Walker, M. J. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00181-19 · Cited by 2,078
Pseudomonas aeruginosa: all roads lead to resistance
Breidenstein, E. B. M., de la Fuente-Núñez, C., & Hancock, R. E. W. (2011) · Trends in Microbiology · doi:10.1016/j.tim.2011.04.005 · Cited by 1,286
Mechanism of Quinolone Action and Resistance
Aldred, K. J., Kerns, R. J., & Osheroff, N. (2014) · Biochemistry · doi:10.1021/bi5000564 · Cited by 1,282
Pal, C., Bengtsson-Palme, J., Kristiansson, E., & Larsson, D. G. J. (2015) · BMC Genomics · doi:10.1186/s12864-015-2153-5 · Cited by 824
Pseudomonas aeruginosa – a phenomenon of bacterial resistance
Strateva, T., & Yordanov, D. (2009) · Journal of Medical Microbiology · doi:10.1099/jmm.0.009142-0 · Cited by 803
Horizontal transfer of antibiotic resistance genes in clinical environments
Lerminiaux, N. A., & Cameron, A. D. S. (2019) · Canadian Journal of Microbiology · doi:10.1139/cjm-2018-0275 · Cited by 802
Pham, T. D. M., Ziora, Z. M., & Blaskovich, M. A. T. (2019) · MedChemComm · doi:10.1039/c9md00120d · Cited by 785
Bacterial Topoisomerase Inhibitors: Quinolone and Pyridone Antibacterial Agents
Mitscher, L. A. (2005) · Chemical Reviews · doi:10.1021/cr030101q · Cited by 781
Bacterial Resistance: Origins, Epidemiology, and Impact
Livermore, D. M. (2003) · Clinical Infectious Diseases · doi:10.1086/344654 · Cited by 586
Mechanism of plasmid-mediated quinolone resistance
Tran, J. H., & Jacoby, G. A. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.082092899 · Cited by 564
Antimicrobial resistance, mechanisms and its clinical significance
Abushaheen, M. A., Muzaheed, Fatani, A. J., Alosaimi, M., Mansy, W., George, M., Acharya, S., Rathod, S., Divakar, D. D., Jhugroo, C., et al. (2020) · Disease-a-Month · doi:10.1016/j.disamonth.2020.100971 · Cited by 511
Yamane, K., Wachino, J.-I., Suzuki, S., Kimura, K., Shibata, N., Kato, H., Shibayama, K., Konda, T., & Arakawa, Y. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00339-07 · Cited by 467
Emergence of plasmid-mediated resistance to quinolones in Enterobacteriaceae
Nordmann, P., & Poirel, L. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki245 · Cited by 425
Fluoroquinolones, tuberculosis, and resistance
Ginsburg, A. S., Grosset, J. H., & Bishai, W. R. (2003) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(03)00671-6 · Cited by 403
Origin of Plasmid-Mediated Quinolone Resistance Determinant QnrA
Poirel, L., Rodriguez-Martinez, J.-M., Mammeri, H., Liard, A., & Nordmann, P. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.8.3523-3525.2005 · Cited by 394
Breakthroughs in bacterial resistance mechanisms and the potential ways to combat them
Khameneh, B., Diab, R., Ghazvini, K., & Fazly Bazzaz, B. S. (2016) · Microbial Pathogenesis · doi:10.1016/j.micpath.2016.02.009 · Cited by 345
Pea, F., Viale, P., & Furlanut, M. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544100-00002 · Cited by 327
Cloning of a Novel Gene for Quinolone Resistance from a Transferable Plasmid in Shigella flexneri 2b
Hata, M., Suzuki, M., Matsumoto, M., Takahashi, M., Sato, K., Ibe, S., & Sakae, K. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.2.801-803.2005 · Cited by 287
Interaction of the Plasmid-Encoded Quinolone Resistance Protein Qnr with Escherichia coli DNA Gyrase
Tran, J. H., Jacoby, G. A., & Hooper, D. C. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.1.118-125.2005 · Cited by 283
Self-citationResistance mechanisms in Campylobacter jejuni
Iovine, N. M. (2013) · Virulence · doi:10.4161/viru.23753 · Cited by 274
Abrupt Emergence of a Single Dominant Multidrug-Resistant Strain of Escherichia coli
Johnson, J. R., Tchesnokova, V., Johnston, B., Clabots, C., Roberts, P. L., Billig, M., Riddell, K., Rogers, P., Qin, X., Butler-Wu, S., et al. (2013) · The Journal of Infectious Diseases · doi:10.1093/infdis/jis933 · Cited by 269
Self-citationPlasmid-Mediated qepA Gene among Escherichia coli Clinical Isolates from Japan
Yamane, K., Wachino, J.-I., Suzuki, S., & Arakawa, Y. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01137-07 · Cited by 253
Konaté, K., Mavoungou, J., Lepengué, A., Aworet-Samseny, R. R., Hilou, A., Souza, A., Dicko, M. H., & M’Batchi, B. (2012) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/1476-0711-11-18 · Cited by 155
Metadata
- Authors
- Hooper, D. C.
- Venue
- Emerging Infectious Diseases
- Published
- 2001-03
- Volume
- 7
- Issue
- 2
- Pages
- 337-341
- ISSN
- 1080-6040 (ISSN-L)
- 1080-6059
- OpenAlex
- W2122273366
- Cited by
- 633
- References
- 32
- FWCI
- 12.16
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.